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Summary Development of thermotolerance is an important phenomenon that must be considered when
thermochemotherapy with multiple heat treatments is used clinically. To study the effect of thermotolerance on
cellular cisplatin (cDDP) sensitivity at 3rC and 43-C in cell lines with different cDDP sensitivities, two Ehrlich
ascites tumour cell lines (one with high cDDP sensitivity and one with in vitro acquired cDDP resistance) were
used. The results indicate that in both cell lines the state of thermotolerance per se did not affect the cDDP
sensitivity at 37C. Thus, general elevations in 'all' heat shock protein levels as found in thermotolerant cells
apparently do not influence cDDP sensitivity to a considerable extent. The sensitising effect of a (second) heat
treatment given simultaneously with a cDDP treatment was less in thermotolerant cells. Thermal enhancement
ratios (TERs) at the 10% survival level for heat doses of 43VC for 30 min or 43VC for 60 min were reduced by
a factor of 1.6 and 2.1 in cDDP-resistant and -sensitive thermotolerant cells respectively, as compared with
control cells. Thus, protection against heat damage in thermotolerant cells seems to be paralleled by
diminished thermal chemosensitisation. Although the effect of thermotolerance on the cDDP-sensitising effect
was less pronounced in the resistant cells, a modifying effect on the resistance factor was not achieved.
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Development of resistance to cisplatin [cDPP, cis-diammine-
dichloroplatinum(II)] is a major limitation to the clinical
success of the drug. The subject of cDDP resistance has been
extensively studied in vitro (reviewed by Andrews and
Howell, 1990), and is most likely a multifactorial pheno-
menon. Decreased cellular drug accumulation, enhanced drug
detoxification by glutathione or metallothioneins, reduced
DNA damage induction and elevated DNA repair capacity
are among the mechanisms reported to contribute to
decreased sensitivity in cDDP-resistant cell lines.
Hyperthermia has been shown to enhance the cytotoxic
action of a number of chemotherapeutic drugs (reviewed by
Engelhardt, 1987), including cDDP. Since hyperthermia has
the potential to interfere with all the above-mentioned
mechanisms that can cause cDDP resistance, it may also be a
suitable modality to interfere with acquired resistance. The
studies performed so far on hyperthermic cDDP sensitisation
in cDDP-resistant cell lines seem to indicate that, at least
with higher temperatures (i.e. 43°C), drug resistance may be
overcome partially (Wallner et al., 1986; Herman et al., 1988;
Mansouri et al., 1989; Konings et al., 1993; Hettinga et al.,
1994).
For the clinical use of thermochemotherapy, optimal treat-
ment schedules of heat and the chemotherapeutic agent must
be determined. If fractionated treatments are given, the
development of thermotolerance is an important phenome-
non to be considered. Thermotolerance, first described by
Gerner and Schneider (1975), is the transient resistant state
of cells to a (second) heat treatment after being pre-exposed
to hyperthermia. For successful use of thermochemotherapy
it is important to know whether the thermotolerant state
influences the cDDP sensitivity of cells at 37C. In ther-
motolerant cells elevated levels of heat shock proteins (HSPs)
have been found. These HSPs seem to play an important role
in thermal resistance (for review see Morimoto et al., 1990).
Transfection studies with HSPs show that transfectants have
increased resistance to heat (Landry et al., 1989; Li et al.,
1991). HSPs may also influence sensitivity to cytostatic drugs.
Transfectants with the human small heat shock protein
HSP27 have been shown to exhibit a multidrug-resistant
phenotype (Huot et al., 1991) that is not P-glycoprotein
mediated. Also, HSP70-overexpressing mutant Chinese ham-
ster fibroblast cells have been found to be resistant to VM26
(Li, 1987). Thus, thermotolerant cells may also have altered
drug sensitivity owing to increased levels of HSPs. Finally, in
addition to being resistant to the toxic effects of heat alone,
thermotolerant cells may also be less susceptible to thermo-
chemosensitisation. A few studies comparing hyperthermic
cDDP sensitisation in control and thermotolerant cells have
been published. Herman et al. (1982) showed that induction
of chronic thermotolerance by altering the heating rate led to
less thermal enhancement of cDDP toxicity. Neilan et al.
(1986), however, found that induction of acute thermotoler-
ance did not affect the interaction of cDDP and 43°C tem-
perature. Also, cDDP sensitivity at 37°C was unchanged.
Recently Majima et al. (1992) also found unaltered cDDP
sensitivity at 37°C when cells developed thermotolerance. Cell
killing by the cDDP-hyperthermia combination treatment
was shown to be lower in thermotolerant cells. Since no
corrections were made for the killing effect of heat alone, it is
hard to distinguish whether the reduced efficacy of the com-
bined treatment is due to reduced heat killing in the ther-
motolerant cells or/and decreased thermal enhancement.
Thus, the effect of thermotolerance on hyperthermic drug
sensitisation is not unequivocally clear. Also, no information
exists on whether thermotolerance effects may differ for cells
with acquired cDDP resistance compared with the parent
cells. Therefore, in the present study the effect of ther-
motolerance on cDDP sensitivity at 37°C, and on the sensitis-
ing effect of a (second) hyperthermia treatment at 43°C, was
determined in cDDP-sensitive (EN) and -resistant (ER) Ehr-
lich ascites tumour cells.
Materials and methods
Materials
cDDP (Aldrich, Milwaukee, WI, USA) was stored as a stock
solution of 1000 lg ml-' in water at - 80°C, in portions of
1 ml in Eppendorf tubes, for at most 1 month. Tissue culture
medium (RPMI-1640), fetal calf serum and newborn calf
serum for the soft agar plates were obtained from Gibco
(Paisley, UK). All other chemicals were purchased from
Sigma (St Louis, MO, USA) or Merck (Darmstadt, Gennany).
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A cloned cDDP-sensitive Ehrlich ascites tumour (EAT) cell
line (EN) and a cloned EAT cell line with in vitro acquired
cDDP resistance (ER) were used. The ER cell line was
developed by culturing EAT parent cells in the presence of
5 ng ml-l cDDP for 4 months, after which these cells were
treated with 8 pg ml1- cDDP for 90 min. The surviving ceLls
were cloned by repeated plating on soft agar. At the 10%
survival level ER cells were 4.8 times more resistant to cDDP
than EN cells (Konings et al., 1993). Both cell lnes were
grown in suspension culture in RPMI-1640 medium supple-
mented with 10% fetal calf serum, 100 units ml-' penicillin
and 100 pg ml-' streptomycin. The doubling time of the cells
was about 11 h. To ensure a stable level ofresistance, the ER
cell line was cultured for no longer than 4 months, after
which period new cells were thawed from liquid nitrogen
storage.
Hyperthermia and cisplati treatments
Hyperthermia was performed in precision waterbaths
(± 0.05C) under continuous gentle shaking. One milliitre of
cell suspension with a cell concentration of 1 x 106ml1' was
incubated in plastic tubes for various times.
To induce thermotoleance, cell suspensions with a cell
concentration of 1 x 106ml-' were treated for Omin at
44-C, after which they were placed in a shaking incubator at
37C for various times to allow development of ther-
motolerance before giving a second treatment with heat and/
or cDDP.
For cDDP treatment, a cDDP stock sample was thawed to
room temperature immediately before each experiment and
diluted in complete medium. A 0.1 ml volume of a
10 x concentrated cDDP solution was added to 0.9 ml of cell
suspension (1.1 x 106cellsml-'). Total incubation time with
cDDP was always 90min.
For simultaneous treatments of hyperthermia and cDDP,
the heat treatment was given during the first part of the
incubation period with cDDP, after which the remaining
incubation was performed in a 37PC waterbath.
Clonogenic survival assay
After treatment with hyperthermia and/or cDDP, the sam-
ples were washed once with 10 ml of medium (RPMI with
10% fetal calf serum), appropriately diluted to obtain about
100 colonies per plate, and plated on 0.5% soft agar plates
with RPMI-1640, supplemented with 15% newborn calf
serum and penicillin and streptomycin. The cells were mixed
with 1 x 10' feeder cells [a mixture of supraletally
(>200 Gy) irradiated EN and ER cells] per plate. The plates
were incubated at 37C in a carbon dioxide incubator for 7
days. Colonies containing more than 50 cells were counted.
The plating efficiency was always over 90%. From the cDDP
survival curves (corrected for heat kill) of each experunent
the concentration needed to kill 90% of the cells (IC90) was
determined by graphical interpolation. From this, thermal
enhancement ratios (TERs) were determined by dividing the
IC,0 for cDDP treatment at 3TC by the IC10 for cDDP
treatment combined with hyperthermia.
Statistical analysis
Sigin levels were calculated using the unpaired
Student's t-test. P<0.05 was considered statistically
significant.
Western blotting
Thermotokrance was induced as described above. After
various tim intervals at 3TC after the thermotoltance trig-
ger, samples were taken from the cell suspenson and washed
three times with phosphate-buffered saline (PBS). For every
2 x 10' cells, 20 p1 of TNMP [10 mM Tris, 5 mm magnesum
chloride, 1O mM sodium chloride, 0.1 mM phenyl methyl sul-
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phonylfluoride (PMSF)] and 5 1I of DNAse I (5 mg/ml) was
added to the cell pellet. After overnight incubation at 4-C an
equal volume of 2 x sample buffer [100mM Tris pH 6.8,
20% glyceroL 10% mercaptoethanol, 4% sodium dodecyl
sulphate (SDS), 0.05% bromphenol blue] was added and
15-l samples were run on 10% polyacrylamide gels. The
proteins were electrophoretically transferred to nitrocellulose
filters and probed with SPA 810 antibody to detect HSP72
and SPA 801 antibody to detect HSP25 (murine equivalent
of human HSP27) (Stressgen, Victoria, Canada).
Resnt
Thermotolerance development in EN and ER cells
Figure 1 shows the development of thermotoleance in EN
(Figure la) and ER (Figure lb) cells after a 10min at 44-C
trigger. The sensitivity to 43"C of previously unheated cells
and of thermotolerant cells 1, 3, 5 and 8 h after the
thermotoklance-inducing heat treatment is shown. As shown
before (Konings et al., 1993), the cDDP-resistant (ER) cells
were less heat sensitive than the EN cells. In Figure lc the
development of thermotokrance is shown by plotting ther-
motolerance ratios at 50% cell kill (TTR_v) as a function of
the time after the first heat treatment. The 1TR50 is the ratio
of the heating time required to kill 50% of thermotolerant
cells and 50% of previously unheated cells. The ther-
motolerant state develops rapidly and remains at least up to
8 h after the triggering dose. Figure 2 shows Western
analyses of HSP25 and HSP72 levels in EN and ER cells
during 1T development. In control cells no HSP25 and
HSP72 was detectable. Expression of both HSPs was clearly
induced in both cell lines 3 h after 10 min at 44C. Up to at
least 8 h after 1T induction, very high levels of both HSPs
were observed in both cell lines.
Since at 5h after 10min 44-C both cell lines have
developed a substantial level of thermotolerance which is
about the same, this time point was used for further studies.
Cisplatin sensitivity (37C) ofcontrol and thermotolerant EN
and ER cells
In Figure 3 the cDDP sensitivity at 37C of the EN and ER
control and thermotolerant cells (5 h after thermotolerance
induction) is shown. At the 10% survival level the control
ER cells are 4.8 times as resistant to the drug as the control
EN cells. The thermotolerant cells of both cell lines were
more sensitive to cDDP treatment at 37C than the control
cells.
To determine whether this increased sensitivity was due to
the state of thermotokrance or to a persisting sensitiing
effect of the 10 min at 44-C treatment to trigger ther-
motoleance, the cDDP sensitivity was investigated by
separating the trigger beat dose (10 min at 44-C) and the
cDDP treatment by 0-8 h incubation at 37C. Figure 4a and
4b shows the cDDP survival curves of EN and ER cells
previously unheated or treated with 10min at 44-C during
cDDP treatment or 3, 5 or 8 h before cDDP treatment.
Heating during the drug treatment gives maximal enhance-
ment of cDDP-induced cell kill. Wben heat and drug treat-
ment are separated by 3 and 5 h, considerable sensitisation is
still found. Eight hours after the heat treatment, however, no
(ER) or almost no (EN) sensitising effect is left. The observed
effect is clearly shown in Figure 4c: the sensitising effect,
expressed as the thermal enhancement ratio (TER) at 10%
survivaL (the ratio between the cDDP dose needed to kill
90% of the cells at 3TC and the cDDP dose killing 90% of
the cells when combined with hyperthermia), of the 10min at
44-C thermotolerance triggering dose decreases with increas-
ing interval times at 37C before the cDDP treatment. This
decay is somewhat more rapid in the ER cells than in the EN
cells. Notably, 8 h after 10 min at 44C considerable levels of
thermotolerance are still observed in both cell lines (Figure
lc), and HSP25/72 levels are still high (Figure 2), whereas at_sioiDm aecDDP s i
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this time point no (ER) or nearly no (EN) altered cDDP
sensitivity is seen any more (Figure 4c). Therefore, it is
unlikely that the thermotolerant status of the cells influences
the cDDP sensitivity (at 37C) directly. Furthermore, this
indicates that a general elevation of HSP levels in ther-
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motolerant cells (as shown in Figure 2) does not appear to
affect the cells' sensitivity to cDDP to a great extent.
Hyperthermic cDDP sensitisation in control and
thermotolerant EN and ER cells
Figure 5 shows the cDDP-sensitising effect of different heat
treatments (5min at 44'C. 30min at 43YC. 60min at 42°C)
with about the same level of cell kill within one cell line. As
can be seen, these different time-temperature combinations
have, in parallel with the same cell k-illing effect, the same
cDDP-sensitising effect. This was found to be the case in
both the EN (Figure 5a) and ER cells (Figure 5b). Thus,
these data are suggestive of a correlation between heat killing
and thermal drug sensitisation. This would imply that, if the
killing effect of a certain heat treatment is decreased, for
instance by induction of thermotolerance, the sensitising
effect would be expected to be lower too. To investigate this,
both control and thermotolerant cells were treated with
cDDP at 3TC and with cDDP combined with 30 and 60 min
a
b
EN cell line
EN cell line
LK ceuull unm
co Ca TT Tm TMrs
ER cell line
Fwe 2 Western blots showing induction of HSP25 (a) and
HSP72 (b) expression in EN and ER cells after 10min at 44-C
treatment. Equal amounts of cells were loaded on the gels. CO,
C8, non-heated control cells 0 and 8h after replacing the
medium; TTI, TT3, T15, TT8, thermotolerant cells 1, 3, 5 and
8 h after thermotokrance trigger.
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Fge 1 Typical experiment showing thermotolerance develop-
ment in EN and ER cells. The 43 C heat sensitivity of EN (a)
and ER (b) cells without pretreatment (A) or 1 (A), 3 (V), 5
(V) or 8 (O)h after 10min at 44C pretreatment is depicted.
Three to six plates were used per data point. Bars (s.d.) are
shown when they exceed the symbol. Survival curves are cor-
rected for the cell kIilling effect of the thermotokrance trigger.
Survival after 10 min at 44 C alone was 71.5% ± 7.6% for EN
and 91.0% ± 10.2% for ER cells. (c) Tbermotokerance ratios at
the 50% survival level (TTRl ) as a function of time at 37C after
thermotolerance trigger (Omin at 44C).
ER-C
ER-TT(5)
EN-TT(5)
IcDDPI (igg ml- )
(treatment at 370C)
Fugwe 3 cDDP sensitivity of EN and ER control and thermo-
tolerant cells 5 h after thermotokrance trigger. Survival curves
are corrected for the cell killing effect of the thermotokerance
trigger. The mean values of at least three independent
experiments are given; bars (s.e.m.) are shown when they exceed
the symbol.
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Figwe 4 Typical experiment showing the cDDP-sensitising effect
of 10 min 44 C in EN and ER cells. cDDP survival curves of EN
(a) and ER (b) cells without pretreatment (A), after simultaneous
min at 44 C treatment (A) and after 10mi 44 C pretreatment
3 (V), 5 (V) or 8 (0) h before cDDP treatment are depicted.
Three to six plates were used per data point. Bars (s.d.) are
shown when they exceed the symbol. Survival curves are cor-
rected for the cell killing effect of the thermotokrance trigger. (c)
The sensitising effect of 10 min at 44 C expressed as the thermal
enhancement ratio (10% survival) as a function of the time
between heat and cDDP treatments.
Fuwe 5 cDDP sensitisation by different time-temperature com-
binations with the same cell killing effect in EN (Sa) and ER (5b)
cells. Survival surves are corrected for the cell killing effect of the
heat treatments. The mean values of at least three independent
expernments are given; bars (s.e.m.) are shown when they exceed
the symbol.
at 43C. cDDP survival curves were constructed and are
shown in Figure 6. From these curves TERs of the 43-C heat
treatments were calculated and are depicted in Figure 7. As
can be deduced from this figure, the sensitising effect of 30 or
60min of43-C hyperthermia in both EN (Figure 7a) and ER
(Figure 7b) thermotolerant cells was found to be decreased
significantly by a factor of 2.1 and 1.6 respectively.
Dcoss
cDDP sensitivity at 37eC ofthermotolerant cells
It is known (Wallner et al., 1986; Eichholtz-Wirth and Hietel,
1990) that when combined treatments of heat and cDDP are
given, maximal potentiation is observed when both
modalities are given simultaneously; the interaction gradually
decreases to the additive level when heat and cDDP are
separated by incubation at 37C. This was also observed in
the present study (Figure 4c). At 8 h after treatment for
Omin at 44 C, almost no enhancement of cDDP toxicity
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Figure 6 Full cDDP survival curves showing the cDDP-sensitising effect of 30 or 60 min at 43VC in EN (a and b) and ER (c and
d) control (a and c) and thermotolerant (b and d) cells (5 h after thermotolerance trigger). Survival curves are corrected for the cell
killing effect of the heat treatment. Mean values of at least three independent experiments are given; bars (s.e.m.) are shown when
they exceed the symbol.
was observed any more. At this time the cells have become
quite resistant to heat toxicity (Figure Ic) because of ther-
motolerance development. Since the cDDP sensitivity of the
cells is equal to the sensitivity of control cells at this time
point, the state of thermotolerance does not seem to confer
resistance against cDDP toxicity to the cells.
Unaltered cDDP sensitivity at 37'C in thermotolerant cells
is in accordance with previously published data of both in
vitro (Neilan et al., 1986; Miller et al., 1989; Majima et al.,
1992) and in vivo (Yano et al., 1993) studies. Also, absence of
interaction of thermotolerance with the cytotoxicity of
several other drugs was observed, e.g. bleomycin toxicity has
been shown to be unaltered in thermotolerant cells in a
number of studies (Morgan et al., 1979; Neilan et al., 1986;
Majima et al., 1992). Morgan et al. (1979) showed the same
for BCNU toxicity. For topoisomerase II inhibitors, how-
ever, a different picture emerges from the literature: cells
made thermotolerant by prior heating have been found to be
resistant to several topoisomerase drugs such as VM26 (Li et
al., 1987), doxorubicin (Ciocca et al., 1992; H.H. Kampinga,
unpublished results), m-AMSA and VP16 (H.H. Kampinga,
unpublished results). Conversely VP16 and VM26 have been
shown to be able to induce heat shock proteins and ther-
motolerance (Li, 1987). For doxorubicin a direct role of
HSP27 in resistance has been suggested. Overexpression of
HSP27 by transfection leads to doxorubicin resistance in
both hamster (Huot et al., 1991) and human (Oesterreich et
al., 1993) cells. The level of HSP27 overexpression is cor-
related with the level of doxorubicin resistance. Also for
cDDP evidence exists for a possible link between HSPs and
resistance. cDDP has also been shown to be able to induce
HSPs (Oesterreich et al., 1991; authors' unpublished data).
cDDP pretreatment can even induce (low) levels of ther-
motolerance (Oesterreich et a!., 1991). Also, a role of overex-
pression of HSP60 in cDDP resistance has been suggested
(Kimura et al., 1993; Nakata et al., 1994). Nevertheless, the
absence of a thermotolerance effect on cDDP sensitivity at
3TC may indicate that the general elevated expression of
HSPs does not affect cDDP sensitivity. However, our data do
not fully exclude the possibility that two counteracting pro-
cesses are taking place, i.e. (decay of) thermal enhancement
of cDDP action by the thermotolerance triggering heat dose
and (development of) resistance to cDDP in parallel to resis-
tance to heat (related to the accumulation of HSPs). Yet,
when cDDP sensitivity of, for example, the ER cells is con-
sidered, it is clear that the same level of thermotolerance is
found 5 and 8 h after the triggering heat dose. At the 5 h
time point the cells are still somewhat more cDDP sensitive;
no alteration in cDDP sensitivity is found at the 8 h time
point. If two opposing effects were taking place, some resis-
tance to cDDP would be expected at the 8 h time point.
So, in general it must be concluded that the mechanisms
that protect thermotolerant cells against heat killing do not
protect the cells against killing by most cytostatic drugs.
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Flgwe 7 cDDP-stising effect of 30 and 60mm at 43-C in EN
(a) and ER (b) control and thermotolerant cik (5 h after ther-
motoerance ind on) xed as thermal enhancement ratio
at 10% survval. The mean values of at least three in nt
experimnts are give bars (SEM) are shown when they exced
the symboL (*P<0.05, **P<0.005).
Certainly a general elevation of HSPs by induang ther-
motokrance does not seem to protect clls against cDDP
toxicity to a considerable extent. Yet it can also be
speulated that different HSPs may have opposing influnces
on cDDP toxicity; therefore a role for specific HSPs in cDDP
sensitivity and reistanc cannot be excluded.
cDDP sensitsation by hyperthermia in thermotolerant cells
The cDDP-sensitising effect of43-C hyperthermia was shown
in the present study to be diminished in thermotolerant cells.
This is in accordance with previously published studies by
Herman et al. (1982) and Majima et al. (1992). On the other
hand, Neilan et al. (1986) found the same level of ther-
mochemosensitisation in control and thermotolerant RIF
cells. Their data, however, show very low hyperthermic
enhancement of cDDP toxicity in the control cells, and
therefore it might be hard to detect a putative reduction in
TER in the thermotolerant cells. A recently published in vimo
study (Yano et al., 1993) is also indicative of less thermal
enhancement of cDDP toxicity in thermotolerant tumours.
Hyperthermic potentiation of some other drugs, such as
bleomycin and BCNU, is also lower in thermotolerant cells
(Morgan et al., 1979; Herman et al., 1982; Neilan et al.,
1986; Majima et al., 1992).
Thus, it seems that themechanisms responsible for hyper-
thermic cell killing and hyperthermic drug sensitisation must
in part be the same. Heat has been shown to cause denatura-
ton and insolubilisation of cellular proteins (Lepock, 1987;
Burgman and Konings, 1992). This leads to, among other
things, anincrease in the protein mass of nuclei isolated from
heated cells (Roti-Roti and Wimward, 1978). Under several
conditions, including thermotolerance, a good correlation has
been found between the extent and duration of this so-caled
nuclear protein aggregation and thermal cellrilling (Kamp-
inga et al., 1989a). This nuclear protein aggregation may also
be one of the major mechanisms responsible for thermal
potentiation of killing by a number of drugs, by hampering
repair of drug-induced DNA damage. Therefore, reduced
protein aggregation or accelerated disag tion, as
observed (Kampinga et al., 1987, 1989a; Wallen and Landis,
1990; Borelli et al., 1992; Laszlo, 1992) in thermotolerant
cells, may not only cause less cell killing, but may also lead
to less inhibition of repair of drug damag, theby decreas-
ing the thermal potentiation of drug action. The latter would
be similar to what has been suggested for thermal radiosen-
siwtsaion chromatin alterations due to heat-induced nuclear
protein aggregation reduce the repairability of damad
DNA (Warters and Roti-Roti, 1979; Saikers et al., 1993),
eading to enhanced radiosensitivity (Kampinga et al., 1989b;
Konings, 1992; Steg et al., 1995).
The observed reduction of TERs was significantly lower in
the istant ER cells than in the sensitie EN cells
(1.59±0.10 vs 2.09±0.14, P<0.005). It is also clear that
TERs in control cells were higher in the cDDP-sensitive cell
line than in the cDDP-resistant subline. Figure 5a shows that
a saturation of cell killing occurs in the EN cell line for doses
of cDDP above 1 pgml-' when combined with hyperther-
mia. In our earier experiments (Konings et al., 1993) we
used only these higher cDDP doses for the survival curves
and fitted straight lines through these by linear regression.
Using this method we found higher TER values for ER cells
than for EN ceIls. Our current data (using lower cDDP
doses) show that cDDP survival curves for the EN cells are
not well represented by straight lines and also show that, by
doing so, the TERs that can be achieved in EN cells may
have been underestimated. Thus, no reduction of resiance
can be obtained by the combination of 43-C hyperthermia
and cDDP in these cell ines. Even though induction of
thermotolerance gives less reduction of TERs in the cDDP-
resistant cells, the absolute TERs are similar in ther-
motokerant cDDP-sensitive and -reistant cells. Therefore it
must be concluded that thermotokrance has no major impact
on the reistance factor.
When thermochemotherapy is given in a fractionated
schedule, thermotoleance can develop. In the present study
we showed that the state of thermotolerance itself does not
seem to affect the sensitivity of tumour cells to cDDP treat-
ment at 3TC to a great extent. However, the efficacy of a
second heat treatment combined with drug applction is
greatly reduced. Both the cell killing and the drugsensitising
effect of the second heat treatment is lowered in the ther-
motolerant cells. Tberefore, to obtain maximal effect of a
heat-drug treatment it is neceary to avoid ther-
motoklrance. When a second treatment consists ofdrug treat-
ment only, thermotoklance does not hamper the efficacy of
this treatment. In the present study it was also shown that
the senstising effects in thermotolerant cDDP-sensitive and
-resistant cells are the same, so thermotolerance development
does not inf cDDP rnce.
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